Department of Psychiatry
The Yale Department of Psychiatry Mission, Vision, Values Statement
The Yale Department of Psychiatry is dedicated to enhancing well-being, facilitating recovery, and reducing the oppression and suffering associated with mental illness. We do this through the pursuit of excellence in education, practice, prevention, policy, and research; the development of transformative leaders; and restorative and reciprocal community engagement. We embrace multiple approaches to learning, levels of analysis, and ways of knowing. Throughout this work, we strive to nurture a diverse community of trainees, staff, faculty, and partnerships, characterized by compassion, dignity, humility, inclusivity, and justice.
About the Department
The Yale Department of Psychiatry is a world leader in patient care, research, and education. Our department prides itself on its diverse and talented faculty, including a cadre of compassionate clinicians, inter-disciplinary teams of talented investigators, and numerous committed and dedicated teachers, as well as a network of able alumni that remain vital to our missions.
As a department, we not only provide the highest quality of patient care, but also lead the nation in discoveries that are transforming our understanding and treatment of mental illness and addiction.
The department’s Psychology Section, with more than 200 full-time and voluntary faculty, is one of the largest and most accomplished groups of psychologists in an academic medical center.
Latest News
- June 14, 2024
McClurkin Awarded Fellowship with American Psychoanalytic Association
- June 14, 2024Source: YaleNews
New Insights Into the Brain Regions Involved in Paranoia
- June 13, 2024
The Heritage & Legacy Project: An intersection of the arts & mental health
- June 13, 2024Source: TIME
‘Absolutely Insufficient:’ How Data Restrictions and Funding Constraints Hamper South Korea’s Suicide Prevention Efforts
- June 13, 2024
Jefferson Chosen to Receive Yale Physician Scientist Development Award
- June 12, 2024
Ranganathan, Cortes-Briones Honored with YNHHS Innovation Award
- June 12, 2024
YSM, VA Researchers Complete First Genome-Wide Association Study of Epiretinal Membrane
- June 11, 2024
How Can Artificial Intelligence Advance Medical Education and Research to Transform Patient Care?
Pioneering Interventional Psychiatric Services: Yale School of Medicine and Yale New Haven Health
00:02:46
Ketamine Clinical Trial
Parkinson disease not only affects a person's mobility, but also many other symptoms in a person with Parkinson disease life. Depression is a very common symptom caused by Parkinson disease, and adequate treatment is imperative for patients to feel their best. Through collaborations between Drs. Sophie E. Holmes and Gerard Sanacora of Psychiatry and the Movement Disorders group, researchers are conducting the first clinical trial of ketamine as an antidepressant in PD. Due to how it works in the brain – its ability to help form new synapses – they have strong reason to believe it will effectively treat depression, and possibly other symptoms, in PD. Using brain imaging before and after treatment will help to determine how it works in the brains of people with Parkinson’s for the first time. The trial is taking place at the Yale New Haven Psychiatric Hospital. In this video, hear more about the trial from Drs. Holmes and Sanacora and from Brenda, who talks about her experience participating in this groundbreaking research.
Department of Psychiatry Upcoming Events
Everyone Samuel Wilkinson, MD
Everyone Dhananjay Bhaskar, PhD - Brian Zaboski, PhD
Restricted All Day
Department of Psychiatry Diversity, Equity and Inclusion Upcoming Events
Everyone Samuel Wilkinson, MD
Everyone Dhananjay Bhaskar, PhD - Brian Zaboski, PhD
Restricted All Day